Midbrain dopaminergic cell loss in parkinson's disease: Computer visualization
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Computer visualization techniques were used to map the distribution of dopaminergic neurons within midbrain tissue sections from 5 parkinsonian patients and 3 age‐matched control subjects. The Parkinsonian brains had over 50% fewer dopaminergic neurons within the midbrain than age‐matched normal brains. The cell loss occurred within the combined substantia nigra (dopaminergic nucleus A9) and retrorubral (dopaminergic nucleus A8) areas (> 61%) and the ventral tegmental area (dopaminergic nucleus A10) (> 42%). The cell loss was greatest within the ventral portion of the substantia nigra zona compacta. The specific pattern of cell loss is very similar to the pattern of cells that project to the striatum (as opposed to cortical and limbic sites) in animal neuroanatomical tracing experiments. These data suggest that Parkinson's disease preferentially destroys midbrain dopaminergic neurons in nuclei A8, A9, and A10, which project to the striatum.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Estimation of nuclear population from microtome sections
Abercrombie, M. (1946) · The Anatomical Record · doi:10.1002/ar.1090940210 · Cited by 4,363 · cited 1×
“This number was corrected for split cell error using the formula of Abercrombie [9].”
MethodDOPAMINE (3-HYDROXYTYRAMINE) AND BRAIN FUNCTION
HORNYKIEWICZ, O. (1966) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)07154-6 · Cited by 1,442
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Fallon, J. H., & Moore, R. Y. (1978) · Journal of Comparative Neurology · doi:10.1002/cne.901800310 · Cited by 1,169
Central Catecholamine Neuron Systems: Anatomy and Physiology of the Dopamine Systems
Moore, R. Y., & Bloom, F. E. (1978) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.01.030178.001021 · Cited by 926
Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., & Agid, Y. (1983) · Brain Research · doi:10.1016/0006-8993(83)90993-9 · Cited by 726
HENN, F. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.12.1633-b · Cited by 506
Selectivity of the Parkinsonian Neurotoxin MPTP: Toxic Metabolite MPP + Binds to Neuromelanin
D'Amato, R. J., Lipman, Z. P., & Snyder, S. H. (1986) · Science · doi:10.1126/science.3080808 · Cited by 296
Hallman, H., Lange, L., Olson, L., Strömberg, I., & Jonsson, G. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb07120.x · Cited by 281
Cited by
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756
Wernig, M., Zhao, J.-P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, V., Constantine-Paton, M., Isacson, O., & Jaenisch, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801677105 · Cited by 1,216
Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway
Deumens, R., Blokland, A., & Prickaerts, J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7891 · Cited by 758
Duty, S., & Jenner, P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01426.x · Cited by 753
Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684
Brooks, D. J., Ibanez, V., Sawle, G. V., Quinn, N., Lees, A. J., Mathias, C. J., Bannister, R., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Annals of Neurology · doi:10.1002/ana.410280412 · Cited by 626
Giovannoni, G. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.4.423 · Cited by 587
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains
Sofic, E., Paulus, W., Jellinger, K., Riederer, P., & Youdim, M. B. H. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02017.x · Cited by 524
Disease‐specific patterns of locus coeruleus cell loss
German, D. C., Manaye, K. F., White, C. L., Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., & Mann, D. M. A. (1992) · Annals of Neurology · doi:10.1002/ana.410320510 · Cited by 512
Self-citationOn Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate?
Doty, R. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30123-0 · Cited by 405
The MPTP model of Parkinson's disease
Smeyne, R. J., & Jackson-Lewis, V. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.017 · Cited by 377
Hudson, J. L., van Horne, C. G., Strömberg, I., Brock, S., Clayton, J., Masserano, J., Hoffer, B. J., & Gerhardt, G. A. (1993) · Brain Research · doi:10.1016/0006-8993(93)90576-9 · Cited by 377
Leenders, K. L., Salmon, E. P., Tyrrell, P., Perani, D., Brooks, D. J., Sager, H., Jones, T., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120034007 · Cited by 376
Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., & Isacson, O. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi178 · Cited by 361
“Caudally and laterally located ventral DA cells within A9 DA neurons are the most vulnerable cells in PD (14,15).”
BackgroundComparison of in vitro antioxidant and antiradical activities of L-tyrosine and L-Dopa
Gülçin, İ. (2007) · Amino Acids · doi:10.1007/s00726-006-0379-x · Cited by 357
Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., & Dannals, R. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340331 · Cited by 320
GERMAN, D. C., MANAYE, K. F., SONSALLA, P. K., & BROOKS, B. A. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb24523.x · Cited by 318
Self-citationIron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis
Jellinger, K., Kienzl, E., Rumpelmair, G., Riederer, P., Stachelberger, H., Ben‐Shachar, D., & Youdim, M. B. H. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08362.x · Cited by 313
The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies
Seidel, K., Mahlke, J., Siswanto, S., Krüger, R., Heinsen, H., Auburger, G., Bouzrou, M., Grinberg, L. T., Wicht, H., Korf, H., et al. (2015) · Brain Pathology · doi:10.1111/bpa.12168 · Cited by 306
Dopamine receptors and transporters in Parkinson's disease and schizophrenia
Seeman, P., & Niznik, H. B. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.10.2197154 · Cited by 300
Vos, M. (2010) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2010.00139 · Cited by 280
Jang, H., Boltz, D. A., Webster, R. G., & Smeyne, R. J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.08.001 · Cited by 273
The role of the striatum and hippocampus in planning: A PET activation study in Parkinson's disease
Dagher, A. (2001) · Brain · doi:10.1093/brain/124.5.1020 · Cited by 259
Dopamine dysregulation syndrome in Parkinson's disease
Evans, A. H., & Lees, A. J. (2004) · Current Opinion in Neurology · doi:10.1097/01.wco.0000137528.23126.41 · Cited by 257
Midbrain dopaminergic neurons (nuclei A8, A9, and A10): Three‐dimensional reconstruction in the rat
German, D. C., & Manaye, K. F. (1993) · Journal of Comparative Neurology · doi:10.1002/cne.903310302 · Cited by 255
Self-citationPositron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Bohnen, N. I., Albm, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600276 · Cited by 254
Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
Nurmi, E., Ruottinen, H. M., Bergman, J., Haaparanta, M., Solin, O., Sonninen, P., & Rinne, J. O. (2001) · Movement Disorders · doi:10.1002/mds.1139 · Cited by 219
Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss
Lee, Y., Karuppagounder, S. S., Shin, J.-H., Lee, Y.-I., Ko, H. S., Swing, D., Jiang, H., Kang, S.-U., Lee, B. D., Kang, H. C., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3500 · Cited by 214
Massman, P. J., Delis, D. C., Butters, N., Levin, B. E., & Salmon, D. P. (1990) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/01688639008401015 · Cited by 206
The vulnerable ventral tegmental area in Parkinson’s disease
Alberico, S. L., Cassell, M. D., & Narayanan, N. S. (2015) · Basal Ganglia · doi:10.1016/j.baga.2015.06.001 · Cited by 192
“The VTA extends laterally from the midline (0 mm) to 4 mm and from 4 mm caudal to the mammillary bodies to 9 mm [11].”
BackgroundMethodInfluentialCollier, T. J., Lipton, J., Daley, B. F., Palfi, S., Chu, Y., Sortwell, C., Bakay, R. A. E., Sladek, J. R., & Kordower, J. H. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.11.013 · Cited by 162
Ma, S. Y., Röyttä, M., Rinne, J. O., Collan, Y., & Rinne, U. K. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00100-7 · Cited by 160
Yoshimoto, Y., Lin, Q., Collier, T. J., Frim, D. M., Breakefield, X. O., & Bohn, M. C. (1995) · Brain Research · doi:10.1016/0006-8993(95)00596-i · Cited by 146
Ding, Y. M., Jaumotte, J. D., Signore, A. P., & Zigmond, M. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02415.x · Cited by 137
In vivo imaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
Hansen, A. K., Knudsen, K., Lillethorup, T. P., Landau, A. M., Parbo, P., Fedorova, T., Audrain, H., Bender, D., Østergaard, K., Brooks, D. J., et al. (2016) · Brain · doi:10.1093/brain/aww098 · Cited by 128
Wang, Q., Li, W.-X., Dai, S.-X., Guo, Y.-C., Han, F.-F., Zheng, J.-J., Li, G.-H., & Huang, J.-F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161032 · Cited by 88
“neuron degeneration and loss [3] in the substan-”
BackgroundVulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease
González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65
Kleinknecht, A., Popova, B., Lázaro, D. F., Pinho, R., Valerius, O., Outeiro, T. F., & Braus, G. H. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006098 · Cited by 58
Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease
Cuevas, E., Burks, S., Raymick, J., Robinson, B., Gómez-Crisóstomo, N. P., Escudero-Lourdes, C., Lopez, A. G. G., Chigurupati, S., Hanig, J., Ferguson, S. A., et al. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1859729 · Cited by 57
Metadata
- Authors
- German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., & Saper, C. B.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1989-10
- Volume
- 26
- Issue
- 4
- Pages
- 507-514
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2030187260
- Cited by
- 396
- References
- 25
- FWCI
- 13.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.